instruction:
Compose a new way to ask the same question. The new question must be asking the exact same thing as the original question does. Without any other information, you should be able to tell that the original question and the new question are the same. Preserve bracketed phrases in your new question. You can change the rest of the question provided the above requirements are satisfied. The new question must have a natural, fluent formulation, as if it were composed by a native English speaker. You will be given three pieces of information to help you create better questions. Those are: "Answer": the answer to the question, e.g., "Honolulu". "Answer Type": the type of the answer, e.g., "Location". "Auxiliary Information" is a detailed description of some concepts mentioned in the question, if any.
question:
original question: which organization type does include [William McKinley High School]?
answer: high school
answer type: Fictional Organization Type.
answer:
Name the organization type which includes [William McKinley High School].


question:
original question: What is the award category for nomination announcement [November 13, 2013 UK Festival Awards Nomination Announcement]?
answer: uk festival award for best line-up, uk festival award for agency of the year, uk festival award for best use of new technology...
answer type: Award category.
auxiliary information: The announcement of a jury-decided nominee shortlist for the 2014 UK Festival Awards took place on November 13th, 2013.
answer:
[November 13, 2013 UK Festival Awards Nomination Announcement] is a nomination announcement for what categories of awards?


question:
original question: What type of drug is [Adalimumab 50 kit]?
answer: biologic
answer type: Drug formulation category.
auxiliary information: Adalimumab kit, for subcutaneous / topical administration, consisting of: 50mg/mL adalimumab.Indications:HUMIRA is a tumor necrosis factor (TNF) blocker indicated for treatment of:  Rheumatoid Arthritis (RA) (1.1)   Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.  Juvenile Idiopathic Arthritis (JIA) (1.2)   Reducing signs and symptoms of moderately to severely active polyarticular JIA in pediatric patients 4 years of age and older.  Psoriatic Arthritis (PsA) (1.3)   Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.  Ankylosing Spondylitis (AS) (1.4)   Reducing signs and symptoms in adult patients with active AS.  Crohn‚Äôs Disease (CD) (1.5)   Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn‚Äôs disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.   Plaque Psoriasis (Ps) (1.6)   The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
answer:

[Adalimumab 50 kit] is which kind of drug?